What's up Doc..., page-7

not for another few weeks if you please although i suspect the quarterly will define the tone in the short term.

I suspect management will be keeping a relatively low profile as the various business streams are matured.

This will ensure maximum immediate value will be extracted. Nothing worse than a cheap takeover leaving the punters out of pocket.

As a minimum we want.

1. Cash flow positive covering all R&D costs
2. Global distribution of Evolis + and associated health care products
3. Successful Ph1 Therapeutics trial with tri-body anti-body
4. Multiple cancer diagnostic tests with Quest
5. further product development with Pacific Edge and Global dist of CX Bladder
5. Licensing deal with Fujikura Kasei with royalties

Without this suite of revenue producing streams we are being undersold. 1$B plus imo.

GLTA